Pay in 4 interest-free payments of $5.66 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
The peptide is currently sold for research purposes only and lacks FDA approval for human therapeutic use
Blend Composition BPC-157 Gastric Pentadecapeptide 50% TB-500 Thymosin 4 Fragment 50% Reference data BPC-157 + TB-500 Blend specifications Composition BPC-157 + TB-500 (50/50 split) Per-vial amount 5mg + 5mg (10mg) or 10mg + 10mg (20mg) Components Two research peptides Appearance White lyophilized powder Solubility Soluble in bacteriostatic water Purity 99.28% Research applications Where BPC-157 + TB-500 Blend is used in research Areas of study described in the published literature
Intense exercise often leads to muscle microtears, which cause inflammation and soreness
Study in the animal and in man
(PRO TIP: the prefix eu- means good or well, and in medicine is often used to mean normal.) Patients with euglycemic DKA, like DKA and HHS, have an insulin deficiency
Researchers are hoping that the study can move to a clinical trial soon and that it will be successful in treating other forms of herpes and HIV as well
